Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 23;10(7):1489.
doi: 10.3390/biomedicines10071489.

Association between Advanced Glycation End-Products and Sarcopenia in Patients with Chronic Kidney Disease

Paolo Molinari  1 , Lara Caldiroli  1 , Elena Dozio  2 , Roberta Rigolini  3 , Paola Giubbilini  3 , Massimiliano M Corsi Romanelli  2   3 , Giuseppe Castellano  1   4 , Simone Vettoretti  1
Affiliations

Association between Advanced Glycation End-Products and Sarcopenia in Patients with Chronic Kidney Disease

Paolo Molinari et al. Biomedicines. .

Abstract

Background: In patients with chronic kidney disease (CKD), there is an overproduction and accumulation of advanced glycation end-products (AGEs). Since AGEs may have detrimental effects on muscular trophism and performance, we evaluated whether they may contribute to the onset of sarcopenia in CKD patients.

Methods: We enrolled 117 patients. The AGEs were quantified by fluorescence intensity using a fluorescence spectrophotometer and soluble receptor for AGE (sRAGE) isoforms by ELISA. As for the sarcopenia definition, we used the European Working Group on Sarcopenia in Older People (EWGSOP2) criteria.

Results: The average age was 80 ± 11 years, 70% were males, and the mean eGFR was 25 + 11 mL/min/1.73 m2. Sarcopenia was diagnosed in 26 patients (with a prevalence of 22%). The sarcopenic patients had higher levels of circulating AGEs (3405 ± 951 vs. 2912 ± 722 A.U., p = 0.005). AGEs were higher in subjects with a lower midarm muscle circumference (MAMC) (3322 ± 919 vs. 2883 ± 700 A.U., respectively; p = 0.005) and were directly correlated with the gait test time (r = 0.180, p = 0.049). The total sRAGE and its different isoforms (esRAGE and cRAGE) did not differ in patients with or without sarcopenia.

Conclusions: In older CKD patients, AGEs, but not sRAGE, are associated with the presence of sarcopenia. Therefore, AGEs may contribute to the complex pathophysiology leading to the development of sarcopenia in CKD patients.

Keywords: advanced glycation end-products (AGEs); chronic kidney disease (CKD); cleaved RAGE (cRAGE); endogenous secretory RAGE (esRAGE); sarcopenia; soluble receptor for AGE (sRAGE).

PubMed Disclaimer

Conflict of interest statement

S.V. served as a consultant for the advisory boards of Vifor Pharma, Merk Sharp & Dohme, and Astra Zeneca and held a sponsored lecture by Shär.

Figures

Figure 1
Figure 1
Linear regression model of comparison between AGEs, handgrip strength, and gait test time; AGEs, Advanced Glycation End-products.
See this image and copyright information in PMC

References

    1. Dozio E., Vettoretti S., Lungarella G., Messa P., Romanelli M.C. Sarcopenia in Chronic Kidney Disease: Focus on Advanced Glycation End Products as Mediators and Markers of Oxidative Stress. Biomedicines. 2021;9:405. doi: 10.3390/biomedicines9040405. - DOI - PMC - PubMed
    1. Stenvinkel P., Larsson T.E. Chronic Kidney Disease: A Clinical Model of Premature Aging. Am. J. Kidney Dis. 2013;62:339–351. doi: 10.1053/j.ajkd.2012.11.051. - DOI - PubMed
    1. Fahal I.H. Uraemic sarcopenia: Aetiology and implications. Nephrol. Dial. Transplant. 2014;29:1655–1665. doi: 10.1093/ndt/gft070. - DOI - PubMed
    1. Esposito K., Chiodini P., Ceriello A., Giugliano D. A nomogram to estimate the proportion of patients at hemoglobin A1c target. Acta Diabetol. 2014;51:305–311. doi: 10.1007/s00592-012-0370-9. - DOI - PubMed
    1. De Souza V.A., De Oliveira D., Mansur H.N., Fernandes N.M.D.S., Bastos M.G. Sarcopenia in Chronic Kidney Disease. J. Bras. Nefrol. 2015;37:95–105. doi: 10.5935/0101-2800.20150014. - DOI - PubMed